Loading
A phase 3 trial testing Setidegrasib in pancreatic ductal adenocarcinoma, now recruiting.
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer is a phase 3 interventional study registered as NCT07409272, led by Astellas Pharma Global Development, and recruiting on the registry. Official title: A Phase 3, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma. Planned enrolment is 614 participants (estimated). The study started in 2026-02-17 and primary completion is expected in 2029-08-31. No results have been posted on ClinicalTrials.gov.
Shares Setidegrasib, Astellas.
Shares Setidegrasib, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma.
Shares Astellas, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Astellas, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Astellas, Pancreatic ductal adenocarcinoma.